Origimm receives Seed funding

Origimm has successfully closed the pre-Seed phase, reaching and even exceeding all projected scientific and business milestones. On May 16, 2014 Origimm successfully raised a Seed financing round from the main Austrian stake holder, AWS. This additional investment will support further development of Origimm’s acne vaccine towards end of discovery and the beginning of pre-clinical phase.